FRANKFURT, Oct 23 (Reuters) - The CEO of Swiss

pharmaceuticals giant Roche said competition authorities

should not allow the controlling shareholder of Novo Nordisk

to acquiring contract drug manufacturer Catalent ( CTLT )

.

"It's not a problem for us, but it could be a problem for

other smaller players, if there is a restriction in how many

(contract manufacturers) are available. From an industry

perspective, it would be a wrong decision by authorities,"

Roche's CEO Thomas Schinecker said in a media call after the

release of quarterly sales.